Clinical Trial: A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

U.S., Feb. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07399067) titled 'A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis' on Jan. 15.

Brief Summary: The primary objective of this Phase 2 study is to evaluate the efficacy and safety of IBI3002 in patients with moderate to severe Atopic Dermatitis (AD).

Study Start Date: Jan. 30

Study Type: INTERVENTIONAL

Condition: Atopic Dermatitis

Intervention: DRUG: IBI3002

IBI3002 will be administered subcutaneously at the assigned dose level and dosing interval.

DRUG: Placebo

Matched placebo will be administered subcutaneously at the same schedule as IBI3002.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Innovent...